Henrui Pharmaceuticals Karelli Pearl Single Resistance is included in the National Health Insurance Directory

Lung, liver, esophageal cancer, the only reimbursable PD-1 single anti-Carelli pearl monoantigen resistance is Hengrui Pharmaceutical independent research and development and intellectual property rights of human-based PD-1 monoclonal antibodies, can be combined with human PD-1 receptors and block PD-1/PD-L1 access, restore the body's anti-tumor immunity, thus forming a cancer immunotherapy foundation, approved in May 2019.
Since its launch, Karelli Zhudao has been successfully approved as one of the four major adaptors of lung cancer, liver cancer, esophageal cancer and lymphoma with excellent data from a number of heavyweight studies, and has been recommended by the Chinese Society of Clinical Oncology (CSCO) guidelines for multiple types of tumors, and has been awarded the international academic stage many times.
the PD-1 in this year's health-care negotiations.
, no PD-1/L1 drugs are included in the national health insurance system in the areas of lung, liver and esophageal cancer, except for Carelli's monoantigen.
next year, Karelli's monotherapy will be the only immunotherapy drug among the three cancers that can be reimbursed for health insurance.
round of health care negotiations to include a number of anti-tumor drugs in the national health insurance directory, highlighting the country's care for cancer patients, reflecting the role of the great powers.
epidemiological data show that lung, liver and esophageal cancer accounted for the first, third and fifth place in the number of new cancer patients in China.
Carelli-Zhu single-entry into the national health insurance directory, will greatly ease the financial pressure on patients with related tumors, so that patients get timely and effective treatment, but also make national innovation and health insurance policy dividends to benefit more patients.
efficacy has repeatedly been highly recognized by the international academic community for immunotherapy drugs, in addition to adaptive disorders, on the basis of excellent efficacy to reduce the price of health insurance, help to make innovative drugs better benefit people's livelihood.
As recently as December 19, 2020, The Lancet-Respiratory Medicine, the world's leading academic journal, published its findings online in full.
the study's medium total survival of 27.9 months is the longest survival benefit data in clinical studies of similar lung cancer immunotherapy in the world to date, successfully breaking the two-year mark and bringing new hope to lung cancer patients.
launched in May 2019, Karelli-Zhu single resistance has been approved for Hodgkin's lymphoma, liver cancer, non-squamous non-small lung cancer, esophageal squamous cancer advanced adaptive disorders.
clinical study data show that Karelli-Pearl monoantigen has shown strong efficacy and excellent safety in all cancer species.
In the field of lung cancer, led by Professor Zhou Caixu of Shanghai Lung Hospital affiliated with Tongji University, the results of the world's first phase III study (CameL study) of non-squamous non-small cell lung cancer (NSCLC) first-line immunogenic combined chemotherapy for group Chinese groups showed that the treatment of carelli-zhu single anti-combination chemotherapy driven gene-negative non-small cell lung cancer achieved orR 60.5%, with a medium progression-free survival of 11.3 months.
In the field of liver cancer, a multi-center, Phase II clinical study of china's advanced hepatocellular carcinoma, co-led by Professor Qin Shuxuan of Jinling Hospital in Nanjing and Professor Ren Zhenggang of Zhongshan Hospital affiliated with Fudan University, showed that mOS reached 13.8 months and patients orR reached 14.7%, an increase of 110% compared to the standard second-line targeted treatment program ORR.
the study, published online February 26 in The Lancet Oncology, became the first immunotherapy study of liver cancer in China to reach the top of the Lancet.
the first and only approved hepatic cancer adaptation PD-1 monoantigen with this research.
In the field of esophageal cancer, the results of the Study on Advanced/Metastatic Esophageal Squamous Cancer (ESCORT Study), led by Professor Huang Mirror of the Oncology Hospital of the Chinese Academy of Medical Sciences and Professor Xu Jianming of the Fifth Medical Center of the PLA General Hospital, showed that the patients in the Karelli Pearl Single Anti-Treatment Group had ORR of 20.2% and mOS of 8.3 months, all of which benefited the whole population.
this study broke through the survival bottleneck of esophageal squamous cancer in the past few decades, which is a landmark study in the field of esophageal cancer.
with outstanding data and breakthroughs, ESCORT research is also on the board of The Lancet Oncology.
in the field of lymphoma, the CR rate of patients treated with recurring/refractic classic Hodgkin's lymphoma was 71% for Carelli-Zhudan anti-combined west tyrannosarine, and 100% for patients who continued to respond for 6 months.
the study was published in the American Journal of Clinical Oncology with excellent data.
Karelliju monoantigen is not only supported by high-level evidence-based evidence, but also performs well in terms of safety, and its adverse reactions are mostly level 1, level 2, level 3 and above, the rate of adverse reactions is low, and the patient's tolerance is good.
in the clinical guidelines for lung cancer, liver cancer, esophageal cancer and lymphoma published by CSCO this year, Carelli's single resistance is recommended in the guidelines.
addition, in recent years, Karelli pearl monotherapy has also achieved remarkable therapeutic results in the field of nasopharyngeal cancer, cervical cancer, lung squamous cancer and other diseases.
Innovating practice the responsibility of national pharmaceutical enterprises to assume responsibility as an innovative national pharmaceutical enterprises, Hengrui Pharmaceuticals for many years adhere to the "science and technology-based, create a healthy life for mankind" mission, committed to solving unsolved clinical needs, so that domestic patients "use, affordable" innovative drugs, regain the hope of life and health.
Currently, Hengrui Pharmaceuticals has approved the listing of 7 innovative drugs, of which 6 innovative drugs listed before 2020 have been Alyssib (commodity name: Hengyang), Apatini (commodity name: Aitan), thiaperine gesting (commodity name: Edo), giggletinib (commodity name: Aerini), Karelli Pearl single resistance (commodity name: Erica) and other 5 innovative drugs into the national health insurance directory.
in the health-care catalog adjustment, the company also has three products included in the national health-care catalog.
Among them, the negotiations on ascetamine injections of hydrochloric acid and permendonase injections were successfully negotiated to include or remain in the category B scope of the National Health Insurance Directory, and the centralized procurement of drugs with yew alcohol (albumin binding type) as a second batch of national organization drugs was included in the category B scope of the National Health Insurance Directory.
In the future development, Hengrui will continue to forget the first heart, innovation, and strive to speed up the development of more new drugs, good drugs, continue to improve the accessibility and affordability of drugs, and promote national innovation "going out" for the benefit of patients around the world, better serve the cause of health!